The goal of presently licensed cancer immunology medications for the management of pulmonary cancer is to block immunological checkpoints, including cytotoxic T lymphocyte‐associated antigen 4 (CTLA‐4), PD ligand‐1 (PD‐L1), and programmed death protein‐1 (PD‐1).18 Here, CTLA4 is linked to cancer.